Stay updated with breaking news from Glucagon receptor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stock of NeuroBo Pharmaceuticals, Inc. (NRBO) gained 48 percent on Thursday after the FDA approved the company's Investigational New Drug or IND application for DA-1726, a new dual oxyntomodulin analog agonist. ....
1. In this randomized controlled trial, the triple-hormone-receptor agonist retatrutide was superior to placebo in reducing body weight among patients with obesity. 2. The most common adverse events were gastrointestinal symptoms and increased heart rate. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is an increasingly prevalent chronic disease that can be difficult to effectively ....